// App-Quantinova.ai

2241 : Prophylactic Dose Low Molecular Weight Heparin (dalteparin) For Treatment Of Vaso-Occlusive Pain Crisis In Patients With Sickle Cell Disease

Researchers

Presenter

  • Nirmish Shah

Principal Investigators

  • Shaina Willen

  • Marilyn J. Telen

  • Thomas L. Ortel

Medical Centers

  • Duke University Medical Center, Durham, NC

  • Department of Medicine, Division of Hematologic Malignancies, Duke University Medical Center, Durham, NC

  • Department of Medicine, Duke University, Durham, NC

  • Department of Medicine, Division of Hematologic Malignancies, Duke University Medical Center, Durham, NC

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Deep vein thrombosis

  • Sickle cell anemia

  • Venous thrombosis

Biomarkers

  • Alpha-tubulin N-acetyltransferase 1

  • Catalase

  • D-dimer

  • Lactate dehydrogenase

  • Stearoyl-CoA desaturase

Drug/Treatment

  • dalteparin Subcutaneous

  • Evithrom

  • Heparin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved